Distinctive glycosylation signature and galectin-1 expression in different human breast cancer lines (BCC) and tissues

PERROTTA, RAMIRO; DALOTTO MORENO, TOMAS; MOSES FLORENCIA; CAGNONI, ALEJANDRO J; MARIÑO, KARINA VALERIA; CROCI, DIEGO O.; RABINOVICH, GABRIEL A.; SALATINO, MARIANA

Mar del Plata

Congreso; SAIC/SAI/SAFE 2016; 2016

Galectins can inuence antitumor immune response, angiogenesis and tumor metastasis by interacting with cell surface glycans. Changes in glycosylation observed in malignant cells are specically sensed by lectins and can be used as disease biomarkers. With the goal of investigating the relevance of galectin-glycan interactions in shaping distinct breast cancer phenotypes, we rst selected ve human cell lines that model dierent human breast cancer types. To identify specic glycan structures, we used a panel of biotinylated lectins (Galectin-1 (Gal1), LEL, SNA, PNA, PHA-L and MAA) and analyzed their binding to the cell surface by ow cytometry. We found that highly aggressive lines, as the triple negative MDA-MB- 231 and the HER2-enriched Trastuzumab (TZ)-resistant JIMT-1, showed higher binding of Gal1 (p